Evotec SE stock faces shareholder reshuffle amid major restructuring and deep job cuts

Evotec SE has announced major restructuring, including job cuts and site closures, leading to a significant stock drop and the exit of a key anchor investor. A new investor has emerged as the German biotech navigates cost pressures and a challenging funding environment. The plan aims to streamline operations, cut costs, and focus on high-potential projects, making it a critical development for DACH investors and the European life sciences sector.